Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. (March 2014)

• Record Type: Journal Article
• Authors: Roffeei, Siti Norsyuhada; Mohamed, Zahurin; Reynolds, Gavin P; Said, Mas Ayu; Hatim, Ahmad; Mohamed, Elsa Haniffah Mejia; Aida, Syarinaz Ahmad; Zainal, Nor Zuraida
• Is Part Of: Pharmacogenomics. Volume 15:Number 4(2014)
• Page Start: 477
• Page End: 485
• Publication Date: 2014-03
• Subjects: antipsychotics -- FTO rs9939609 -- LEPR rs1137101 -- metabolic syndrome -- MTHFR rs1801133 -- schizophrenia; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.13.220
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: The occurrence of metabolic syndrome (MS) in schizophrenia patients receiving long-term antipsychotics (APs) contributes to their high mortality rate. We aimed to determine whether genetic polymorphisms of identified candidate genes are associated with MS in our study population.Materials & methods: We recruited 206 schizophrenia patients receiving AP treatment for at least a year. Cross-sectional measurements of weight, height, blood pressure, waist and hip circumference, and other lipid profiles were recorded. Patient DNA was genotyped for 16 candidate gene polymorphisms.Results: Of these patients, 59.7% were found to have MS while 40.3% did not. All metabolic parameters were significantly different between the two groups. Only three of the 16 polymorphisms studied showed significant association with MS; rs9939609 of the FTO gene confers risk for MS (odds ratio [OR]: 1.73, 95% CI: 1.07–2.78, p = 0.026), while rs1137101 of the LEPR gene (OR: 0.47, 95% CI: 0.28–0.80, p = 0.005) and rs1801133 of the MTHFR gene (OR: 0.59, 95% CI: 0.35–0.99, p = 0.049) are protective against MS.Conclusion: Polymorphisms of the FTO, LEPR and MTHFR genes may play a role in MS in Malaysian schizophrenia patients receiving long-term treatment with APs. Original submitted 29 July 2013; Revision submitted 28 October 2013